Literature DB >> 10867143

19p deletion in recurring leiomyosarcoma lesions from the same patient.

P Riva1, L Dalprá, V Gualandri, M Volontè, M Miozzo, R Malgara, A F Conti, L Larizza.   

Abstract

Ten leiomyosarcomas (LMS) affecting the same patient over a period of 3 years were cytogenetically studied to detect nonrandom chromosomal changes with a pathogenetic significance. All tumors, likely metastases of a previous LMS presentation, were classified as small, including eight that developed before chemotherapy; the diagnoses were based on standard immunohistochemistry methods for smooth muscle tumors. Scoring of 613 metaphases revealed monosomy of chromosome 22 in six LMS, monosomy of chromosome 19 in three, and deletion of chromosome 19p in all ten. Interphase fluorescence in situ hybridization (FISH) of the 22-alphoid-specific probe allowed loss of the target chromosome to be detected in four tumors at higher frequencies than those detected by cytogenetics. Double-color FISH of the 19p- and 19q-specific YAC performed on one tumor made it possible to distinguish the monosomic and 19p deleted cells, the relative frequencies of which were found to be 10% and 20%, respectively. The deletion breakpoint could be mapped at 19p13 between YAC 957d12 and YAC 947g4. The recurrence of the 19p deletion in a subset of tumor cells from all of the analyzed LMS suggests that this structural aberration is a significant change in the development of leiomyosarcomas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10867143     DOI: 10.1016/s0165-4608(99)00222-8

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  5 in total

1.  Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors.

Authors:  Antti Ylipää; Kelly K Hunt; Jilong Yang; Alexander J F Lazar; Keila E Torres; Dina C Lev; Matti Nykter; Raphael E Pollock; Jonathan Trent; Wei Zhang
Journal:  Cancer       Date:  2010-09-03       Impact factor: 6.860

Review 2.  Genetic aberrations in soft tissue leiomyosarcoma.

Authors:  Jilong Yang; Xiaoling Du; Kexin Chen; Antti Ylipää; Alexander J F Lazar; Jonathan Trent; Dina Lev; Raphael Pollock; Xishan Hao; Kelly Hunt; Wei Zhang
Journal:  Cancer Lett       Date:  2008-07-22       Impact factor: 8.679

Review 3.  The Role of CDK Pathway Dysregulation and Its Therapeutic Potential in Soft Tissue Sarcoma.

Authors:  Johannes Tobias Thiel; Adrien Daigeler; Jonas Kolbenschlag; Katarzyna Rachunek; Sebastian Hoffmann
Journal:  Cancers (Basel)       Date:  2022-07-12       Impact factor: 6.575

4.  Genetic profiling differentiates second primary tumors from metastases in adult metachronous soft tissue sarcoma.

Authors:  Josefin Fernebro; Ana Carneiro; Anders Rydholm; Henryk A Domanski; Anna Karlsson; Ake Borg; Mef Nilbert
Journal:  Sarcoma       Date:  2009-02-02

5.  DNA copy number alterations in pleomorphic leiomyosarcoma: A case report.

Authors:  Masahiko Kanamori; Taketoshi Yasuda; Shigeharu Nogami; Kayo Suzuki; Takeshi Hori
Journal:  Oncol Lett       Date:  2014-04-03       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.